



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, May 21, 2025
Minutes approved by the board on June 18, 2025

Web link to the meeting video: <https://youtu.be/Nt6vmEmieZY>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20250521-PDAB-document-package.pdf>

Call to order and roll call: Chair Shelley Bailey called the meeting to order at 9:03 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Vice Chair Amy Burns, Dan Hartung, Lauri Hoagland, Dan Kennedy, John Murray

Absent: Robert Judge

The board provided Spanish interpretation and American Sign Language during the meeting.

Declaration of conflict of interest and meetings with entities or individuals related to board activities: John Murray provided a statement. View at video minute [00:01:18](#).

Approval of board minutes: Chair Bailey asked for a motion and second to approve the board minutes as shown on [Pages 5-7](#) of the agenda materials. John Murray made a motion to approve the minutes and Dan Kennedy provided a second. View at video minute [00:04:15](#).

MOTION to approve the April 16, 2025, minutes

Board Vote:

Yes: Dan Hartung, Lauri Hoagland, Dan Kennedy, John Murray, Vice Chair Amy Burns, Chair Shelley Bailey

No: None

Absent: Robert Judge

Abstain: Chris Laman

Motion passed 6-0

Executive director's program update: Ralph Magrish, executive director, Oregon Prescription Drug Affordability Board & Drug Price Transparency Program, provided a program update. View the video at minute [00:05:13](#).

Legislative update: Jesse O'Brien, Division of Financial Regulation (DFR) policy manager, provided an update on prescription drug-related bills proposed in the Oregon Legislative session as shown on [Pages 8-9](#) of the agenda materials. View the video at minute [00:10:18](#).

General Public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Tiffany Westrich-Robertson, AiArthritis & EACH & PIC Coalition; Brian Mayo,



Oregon State Pharmacy Association; Bil Schmidtknecht, Patient Protector; Derek Flowers, Value of Care Coalition; and Dharia McGrew, PhRMA. The board received seven written comments, which are posted on the [PDAB website](#). View the speakers at video minute [00:15:00](#).

Board discussion on timeline, process, and voting methodology for affordability

review determinations: The board reviewed the roadmap, methodology and time frame for affordability reviews, which are included in the agenda materials on [Pages 10-16](#). View the discussion at video minute [00:32:37](#).

Board review and vote on final generic drug report: Cortnee Whitlock, senior policy analyst, led the board in a discussion about the generic drug final report. The board voted to approve the report. View the final report on [Pages 17-40](#) of the agenda materials. View at video minute [01:06:24](#).

MOTION to approve the final generic drug report to send to the Oregon Legislature as discussed by the board today.

Motion made by John Murray with a second by Amy Burns.

Board vote:

Yes: Dan Hartung, Lauri Hoagland, Dan Kennedy, Chris Laman, John Murray, Vice Chair Amy Burns, Chair Shelley Bailey

No: None

Absent for the vote: Robert Judge

Motion passed 7-0

Public comment period for the list of prescription drugs and insulin products

selected for affordability review per ORS 646A.694: View the public comment at video minute [01:15:56](#).

Chair Shelley Bailey called on people who signed up in advance to speak:

Name of speaker	Association to drug under review	Drug
Lindsay Silva	Mother/primary care giver to someone living with Cystic Fibrosis	Creon
Zach Lynkiewicz,	HIV+Hepatitis Policy Institute	Odefsey
Lucy Thornehaven	National Psoriasis Foundation	Humira
Mary Jo Strobel	American Partnership for Eosinophilic Disorders	Dupixent
Ranier Simons	Community Access National Network	Odefsey
Silas Martin	Johnson and Johnson Medicines	Tremfya and Xarelto



The chair read the list of 25 submitted letters the board received. The letters are posted to the [PDAB website](#).

Name	Association to drug under review	Drug
Andrea Todd-Harlin	Sanofi	Dupixent
Gaby Gardiner	Basic Rights Oregon	Odefsey
Anne Murray	Bristol Myers Squibb	Eliquis
Kathleen Costello	Multiple Sclerosis Coalition	Ocrevus
Jane Leo	American Cancer Society, Cancer Action Network	Ibrance, Verzenio, and Perjeta
Kristie Banks	Gilead	Odefsey
Michael Valenta	Johnson & Johnson	Tremfya and Xarelto
Tim Layton	Genentech	Perjeta
Tim Layton	Genentech	Ocrevus
Seth Greiner	National Multiple Sclerosis Society	Ocrevus
Christian Omar Cruz	GSK	Trelegy
Stacie Phan	Boehringer Ingelhim	Jardiance
Cynthia Ransom	Eli Lilly	Emgality, Mounjaro, Taltz, Trulicity, Verzenio, Basaglar
Courtney Piron	Novartis	Cosentyx and Entresto
Albert Faro et al	Cystic Fibrosis Foundation	Creon
Dr. David Bernard Page	Providence Cancer Institute	Perjeta
Isabel Sheridan	Patient	Ibrance
Suzanna Masartis	Community Liver Alliance	Ozempic, Mounjaro, Rybelsus, Trulicity, Humira, Rinvoq
Linda Nelson	Oregon Coalition for Affordability Prescriptions	Trelegy
Mary Wachter	Genentech	Ocrevus, Perjeta
Ranier Simons	Community Access National Network	Odefsey
Scott Bertani	HealthHIV	Odefsey
Mary Jo Strobel,	American Partnership for Eosinophilic Disorders	Dupixent
Molly Guthrie	Susan G. Komen	Ibrance, Verzenio, Perjeta
Sarah Hoffman	Partnership to Advance Cardiovascular Health	Eliquis, Xarelto, Entresto

Announcements: Chair Bailey announced the next meeting will be June 18, 2025, at 9 a.m.

Adjournment: Chair Bailey adjourned the meeting at 11:30 a.m. with all board members in agreement. View at minute [02:04:17](#).